<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01906385</url>
  </required_header>
  <id_info>
    <org_study_id>CTRC 12-02</org_study_id>
    <secondary_id>14-450X</secondary_id>
    <secondary_id>20141749</secondary_id>
    <secondary_id>1R01CA235800-01A1</secondary_id>
    <nct_id>NCT01906385</nct_id>
  </id_info>
  <brief_title>Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)</brief_title>
  <official_title>A Dual Phase 1/2 Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC# 12-02)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Plus Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Plus Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, sequential cohort, open-label, volume and dose escalation study of&#xD;
      the safety, tolerability, and distribution of 186RNL given by convection enhanced delivery to&#xD;
      patients with recurrent or progressive malignant glioma after standard surgical, radiation,&#xD;
      and/or chemotherapy treatment. The study uses a modified Fibonacci dose escalation, followed&#xD;
      by an expansion at the maximum tolerated dose (MTD) to determine efficacy. The starting&#xD;
      absorbed dose is 1mCi in a volume of 0.660mL.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2015</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>90 days</time_frame>
    <description>Evaluation of any toxicity associated with research treatment per Common Toxicity Criteria for Adverse Events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose Distribution</measure>
    <time_frame>3 days</time_frame>
    <description>SPECT imaging of the radioactive materials spread across the tumor and surrounding brain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>90 days</time_frame>
    <description>Evaluation of overall response rate by RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>6 months</time_frame>
    <description>Disease specific progression free survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>Rhenium Liposome Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rhenium Liposome Treatment</intervention_name>
    <description>At the time of stereotactic biopsy a catheter will be placed within the tumor using stereotactic guidance. Once the patient has adequately recovered from the procedure as determined by the neurosurgeon, 186RNL will be infused through the catheter at the predetermined dose. Spectroscopic imaging will then be obtained at predefined time points to visualize the distribution of the 186RNL as well as calculated the actual dose retained within the tumor. Patients will be monitored longitudinally for evidence of toxicity and response by MRI.</description>
    <arm_group_label>Rhenium Liposome Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. At least 18 years of age&#xD;
&#xD;
          2. Ability to understand the purposes and risks of the study and has signed a written&#xD;
             informed consent form approved by the investigator's IRB/Ethics Committee&#xD;
&#xD;
          3. Histologically confirmed glioma&#xD;
&#xD;
          4. Progression by RANO criteria following standard treatment options with known survival&#xD;
             benefit (Temozolomide, Radiation, and Tumor Treating Fields [unless unwilling])&#xD;
&#xD;
          5. Patients who receive treatment with antiepileptic medications must have a two week&#xD;
             history of stable dose of antiepileptic without seizures prior to dosing&#xD;
&#xD;
          6. Patients with corticosteroid requirements to control cerebral edema must be maintained&#xD;
             at a stable or decreasing dose for a minimum of two weeks without progression of&#xD;
             clinical symptoms&#xD;
&#xD;
          7. A volume of enhancing tumor which falls within the treatment field volume being&#xD;
             evaluated in the respective cohort (see 4.1 Design)&#xD;
&#xD;
          8. ECOG performance status of 0 to 2&#xD;
&#xD;
          9. Life expectancy of at least 2 months&#xD;
&#xD;
         10. Acceptable liver function:&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 times upper limit of normal&#xD;
&#xD;
               -  AST (SGOT) and ALT (SGPT) ≤ 3.0 times upper limit of normal (ULN);&#xD;
&#xD;
         11. Acceptable renal function:&#xD;
&#xD;
               -  Serum creatinine ≤1.5xULN&#xD;
&#xD;
         12. Acceptable hematologic status (without hematologic support):&#xD;
&#xD;
               -  ANC ≥1000 cells/uL&#xD;
&#xD;
               -  Platelet count ≥100,000/uL&#xD;
&#xD;
               -  Hemoglobin ≥9.0 g/dL&#xD;
&#xD;
         13. All women of childbearing potential must have a negative serum pregnancy test and male&#xD;
             and female subjects must agree to use effective means of contraception (surgical&#xD;
             sterilization or the use or barrier contraception with either a condom or diaphragm in&#xD;
             conjunction with spermicidal gel or an IUD) with their partner from entry into the&#xD;
             study through 6 months after the last dose&#xD;
&#xD;
             For part 2:&#xD;
&#xD;
         14. Bevacizumab naïve glioblastoma with no more than 1 recurrence&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The subject has evidence of acute intracranial or intratumoral hemorrhage either by&#xD;
             MRI or computerized tomography (CT) scan. Subjects with resolving hemorrhage changes,&#xD;
             punctate hemorrhage, or hemosiderin are eligible.&#xD;
&#xD;
          2. The subject is unable to undergo MRI scan (eg, has pacemaker).&#xD;
&#xD;
          3. The subject has not recovered to National Cancer Institute (NCI) Common Terminology&#xD;
             Criteria for Adverse Events (CTCAE) v4.0 Grade ≤ 1 from AEs (except alopecia, anemia&#xD;
             and lymphopenia) due to surgery, antineoplastic agents, investigational drugs, or&#xD;
             other medications that were administered prior to study.&#xD;
&#xD;
          4. The subject is pregnant or breast-feeding.&#xD;
&#xD;
          5. The subject has serious intercurrent illness, as determined by the treating physician,&#xD;
             that would compromise either patient safety or study outcomes such as:&#xD;
&#xD;
               -  hypertension (two or more blood pressure readings performed at screening of &gt; 150&#xD;
                  mmHg systolic or &gt; 100 mmHg diastolic) despite optimal treatment&#xD;
&#xD;
               -  Non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
               -  Clinically significant cardiac arrhythmias&#xD;
&#xD;
               -  Untreated hypothyroidism&#xD;
&#xD;
               -  Uncontrolled systemic infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure or unstable angina pectoris within 3 months&#xD;
                  prior study drug&#xD;
&#xD;
               -  Myocardial infarction, stroke, transient ischemic attack within 6 months&#xD;
&#xD;
               -  Known active malignancy (other than glioma) except non-melanoma skin cancer or&#xD;
                  carcinoma in-situ in the cervix&#xD;
&#xD;
          6. The subject has inherited bleeding diathesis or coagulopathy with the risk of bleeding&#xD;
&#xD;
          7. The subject has received any of the following prior anticancer therapy:&#xD;
&#xD;
               -  Non-standard radiation therapy such as brachytherapy, systemic radioisotope&#xD;
                  therapy, or intra-operative radiotherapy (IORT) to the target site.&#xD;
&#xD;
               -  Radiation therapy within 12 weeks of screening&#xD;
&#xD;
               -  Systemic therapy (including investigational agents and small-molecule kinase&#xD;
                  inhibitors) or non-cytotoxic hormonal therapy (eg, tamoxifen) within 14 days or 5&#xD;
                  half-lives, whichever is shorter, prior first dose of study drug&#xD;
&#xD;
               -  Biologic agents (antibodies, immune modulators, vaccines, cytokines) within 21&#xD;
                  days prior to first dose of study drug&#xD;
&#xD;
               -  Nitrosoureas or mitomycin C within 42 days, or metronomic/protracted low-dose&#xD;
                  chemotherapy within 14 days, or other cytotoxic chemotherapy within 28 days,&#xD;
                  prior to first dose of study drug&#xD;
&#xD;
               -  Prior treatment with carmustine wafers&#xD;
&#xD;
               -  Patients who are currently receiving any other investigational agents and/or who&#xD;
                  have received an investigational agent in the prior 28 days&#xD;
&#xD;
          8. Multifocal progression or involvement of the leptomeninges&#xD;
&#xD;
          9. Psychiatric illness/social situations that would limit compliance with the study&#xD;
             requirements&#xD;
&#xD;
         10. Infratentorial disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew J Brenner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Epp Goodwin</last_name>
    <phone>210-450-5798</phone>
    <email>goodwine@uthscsa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maggie Tomasini</last_name>
    <phone>210-450-5962</phone>
    <email>ctrcreferral@uthscsa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Thomas</last_name>
      <phone>214-648-7094</phone>
      <email>Tiffany.Thomas@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Toral Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Summer Stovall</last_name>
      <phone>713-745-4243</phone>
      <email>sstovall@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Weinberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Cancer Therapy and Research Center at UTHSCSA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Epp Goodwin</last_name>
      <phone>210-450-5798</phone>
    </contact>
    <investigator>
      <last_name>Andrew J Brenner, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John R Floyd, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William T Phillips, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 11, 2012</study_first_submitted>
  <study_first_submitted_qc>July 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2013</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioma</keyword>
  <keyword>Brain Tumor</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Glioblastoma</keyword>
  <keyword>Recurrent Glioblastoma</keyword>
  <keyword>Rhenium</keyword>
  <keyword>Rhenium Nanoliposome</keyword>
  <keyword>Brain Cancer</keyword>
  <keyword>GBM</keyword>
  <keyword>High Grade Glioma</keyword>
  <keyword>Glioblastoma Multiform</keyword>
  <keyword>Grade IV Astrocytoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

